Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data

Table 3

Univariate and multivariate Cox proportional hazards analysis for CPEB3 expression.

Characteristics	Univariate analysis		Multivariate analysis
	Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value
T stage (T0-2 vs. T3-4)	2.056 (1.502-2.814)	<0.001	1.177 (0.754-1.836)	0.474
N stage (N0 vs. N1-3)	1.711 (1.271-2.304)	<0.001	3.959 (1.152-13.602)	0.029
M stage (M0 vs. M1)	1.734 (0.915-3.287)	0.092	1.507 (0.56-4.056)	0.417
Clinical stage (stage 0-II vs. stage III-IV)	1.579 (1.177-2.118)	0.002	0.546 (0.154-1.935)	0.348
Melanoma Clark level (I-III vs. IV-V)	2.117 (1.472-3.045)	<0.001	1.259 (0.771-2.056)	0.357
Gender (female vs. male)	1.164 (0.872-1.554)	0.301
Age (≤60 vs. >60)	1.678 (1.266-2.225)	<0.001	1.167 (0.785-1.735)	0.447
Height (>170 vs. ≤170)	0.96 (0.625-1.475)	0.853
Weight (≤80 vs. >80)	0.853 (0.557-1.307)	0.466
BMI (≤25 vs. >25)	0.819 (0.508-1.321)	0.414
Tumor tissue site (extremities vs. trunk)	0.941 (0.693-1.278)	0.698
Melanoma ulceration (no vs. yes)	2.087 (1.494-2.916)	<0.001	1.793 (1.209-2.66)	0.004
CPEB3 (low vs. high)	0.609 (0.464-0.799)	<0.001	0.45 (0.305-0.664)	<0.001